For patients with DCIS, risk of death higher for women under 35, black women
the ONA take:
Women diagnosed with ductal carcinoma in situ have a 20-year breast cancer-specific death rate of 3.3%, with a higher death rate among women diagnosed before age 35 and black women, according to a study published online ahead of print in JAMA Oncology.
For the study, researchers analyzed data from 108,196 women diagnosed with ductal carcinoma in situ of the breast included in the Surveillance, Epidemiology and End Results (SEER) database and compared their risk of dying of breast cancer with that of women in the general population.
Results showed that the 10-year breast cancer-specific death rate after cancer diagnosis was 1.1% and the 20-year rate was 3.3%. Researchers found that women who had a ductal carcinoma in situ diagnosis have a 1.8 times higher risk of death compared those in the general population.
The study also demonstrated that age at diagnosis and black ethnicity were risk factors for death following a ductal carcinoma in situ diagnosis.
Women diagnosed with ductal carcinoma in situ have a 20-year breast cancer-specific death rate of 3.3%.
Sign Up for Free e-newsletters
- A Witness to Letting Go: Nursing Care at the End of Life
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- Age Not a Deterrent to Immunotherapy for Malignant Melanoma
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Patients With Head and Neck Cancer Have Greater Chance of Being Prescribed Opioids
- Medical Terms in Patient Education: Using the Confusing to Explain the Complicated
- Bedside Assessment Tool Improves Worst Pain in Patients With Cancer
- Androgen-Deprivation Therapy for Prostate Cancer May Cause Nocturia, Sleep Disturbance
- USPSTF Rates Ovarian Cancer Screening a D for Asymptomatic, Low-Risk Women
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|